In Brief: Medi-Physics/Amersham Healthcare
Executive Summary
Medi-Physics/Amersham Healthcare: U.S. arm of U.K. parent Amersham signs Adenoscan distribution agreement with Fujisawa USA, which licenses the adenosine injection from Medco Research. Adenoscan was approved May 18 for evaluating cardiac function in patients who cannot undergo a stress test ("The Pink Sheet" May 22, T&G-3). The agreement with Fujisawa will allow Medi-Physics to distribute Adenoscan through its Pharmacy Network of "more than 115 radiopharmacies to their customers," Arlington Heights, Ill.-based Medi-Physics reports. Medi-Physics said July 17 it received an "approvable" letter from FDA for its cardiac perfusion agent Myoview (kit for the preparation of technetium Tc-99m tetrofosmin)...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth